<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561648</url>
  </required_header>
  <id_info>
    <org_study_id>INCAR-DG-DI-205-2020</org_study_id>
    <nct_id>NCT04561648</nct_id>
  </id_info>
  <brief_title>Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.</brief_title>
  <acronym>DEFINITION</acronym>
  <official_title>Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cardiologia Ignacio Chavez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cardiologia Ignacio Chavez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind single center clinical trial to compare the incidence of radial artery occlusion&#xD;
      (RAO) using standard doses of Unfractionated Heparin (UFH) vs. high doses of UFH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radial artery occlusion (RAO) is one of the most common complications in transradial artery&#xD;
      interventions (up to 30% of cases if specific measures are not taken to prevent it) and is&#xD;
      related to the prothrombotic state of the patient, the scarce distal flow to the access site&#xD;
      and the trauma caused to the artery during the procedure.&#xD;
&#xD;
      Currently worldwide, the transradial (TRA) access is the most widely used access for coronary&#xD;
      angiography (in up to 90% of the procedures) because the transradial approach is associated&#xD;
      with lower rates of vascular complications and event mortality (compared to the femoral&#xD;
      access).&#xD;
&#xD;
      Although TRA access is safer, it is not free of complications, being one of the most&#xD;
      important the RAO.&#xD;
&#xD;
      There are universal efforts to reduce RAO improving every aspects of the technique, from the&#xD;
      type of introducer to the hemostasis time to a distal TRA, with evidence suggesting that&#xD;
      higher doses of UFH can also decrease RAO to a greater extent. The decrease in the incidence&#xD;
      of RAO have been proposed to be up to 2.8 times with high doses of UFH (single-center,&#xD;
      retrospective study that compared regular not standard doses of UFH versus higher doses of&#xD;
      UFH) although no proper prospective clinical trial have been undertaken to prove this.&#xD;
&#xD;
      The standard dose that has shown a lower rate of RAO is 5000 IU, which will be compared with&#xD;
      100 IU / Kg of UFH, with a randomized, prospective, double-blind design, with short-term&#xD;
      (24-hour) follow-up with Doppler ultrasound (DUS) and its correlation with plethysmography to&#xD;
      document RAO, and in occluded arteries, there will be a 30-day follow-up to determine the&#xD;
      recanalization (or persistent occlusion) rates by DUS (and plethysmography). In order to&#xD;
      address safety concerns of higher UFH doses, all the potential hemorrhagic complications will&#xD;
      be evaluated during the study follow-up time and higher hemorrhagic risk patients are going&#xD;
      to be excluded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients that are planned to go to an invasive coronary artery angiography with good radial pulse and using the TRA are going to be randomized to two groups. One will receive the standard UFH dose and the other will receive the prespecified high dose (per Kg of body weight) of UFH.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radial artery occlusion (RAO).</measure>
    <time_frame>24 hours.</time_frame>
    <description>The incidence of RAO (with DUS and plethysmography).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radial artery occlusion (RAO).</measure>
    <time_frame>30 days.</time_frame>
    <description>The incidence of RAO (with DUS and plethysmography).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to hemostasis.</measure>
    <time_frame>24 hours.</time_frame>
    <description>Time to hemostasis, from the removal of the introducer sheath to hemostasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameters of the radial artery.</measure>
    <time_frame>24 hours.</time_frame>
    <description>Minimum, maximum and mean diameters of the radial artery by vascular ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of RAO by oximetric plethysmography and DUS.</measure>
    <time_frame>30 days.</time_frame>
    <description>Correlation of plethysmography and DUS for the determination of RAO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic Complications.</measure>
    <time_frame>30 days.</time_frame>
    <description>Compare the incidence of bleeding complications according to The Bleeding Academic Research Consortium 2 (BARC-2) scale:&#xD;
The BARC-2 scale:&#xD;
Type 0&#xD;
Type 1&#xD;
Type 2&#xD;
Type 3&#xD;
Type 4&#xD;
Type 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic Complications.</measure>
    <time_frame>24 hours.</time_frame>
    <description>Compare the incidence of bleeding complications according to the Early Discharge After Transradial Stenting of Coronary Arteries Study (EASY) scale:&#xD;
The EASY scale:&#xD;
Grade I&#xD;
Grade II&#xD;
Grade III&#xD;
Grade IV&#xD;
Grade V</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1988</enrollment>
  <condition>Radial Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>High Dose of Unfractionated Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 IU/Kg of Unfractionated Heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose of Unfractionated Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5000 IU of Unfractionated Heparin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated Heparin</intervention_name>
    <description>Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.</description>
    <arm_group_label>High Dose of Unfractionated Heparin</arm_group_label>
    <arm_group_label>Standard Dose of Unfractionated Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years of age, both genders.&#xD;
&#xD;
          -  Successful transradial acess for an elective diagnostic coronary angiography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight &lt;50 Kg&#xD;
&#xD;
          -  Puncture of the ipsilateral radial artery in the last month.&#xD;
&#xD;
          -  Still ongoing effect of pre-procedural recently used oral anticoagulants.&#xD;
&#xD;
          -  Use of enoxaparin in the past in the last 12 hours prior to the procedure.&#xD;
&#xD;
          -  Use of unfractionated heparin in the last 6 hours prior the procedure&#xD;
&#xD;
          -  Alterations in coagulation or platelets prone to bleeding or thrombotic complications.&#xD;
&#xD;
          -  Anatomical alterations at the radial access site or radial artery.&#xD;
&#xD;
          -  Arteriovenous fistula in the ipsilateral arm.&#xD;
&#xD;
          -  History of major bleeding associated with the use of UFH.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio I Farjat Pasos, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cardiología Ignacio Chávez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guering Eid Lidt, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Nacional de Cardiología Ignacio Chávez</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julio I Farjat Pasos, M.D.</last_name>
    <phone>55 5573 2911</phone>
    <phone_ext>21217</phone_ext>
    <email>julio.farjat@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guering Eid Lidt, M.D.</last_name>
    <phone>55 5573 2911</phone>
    <phone_ext>21217</phone_ext>
    <email>guering@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiología Ignacio Chávez</name>
      <address>
        <city>Mexico City</city>
        <state>Tlalpan</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio I Farjat Pasos, M.D.</last_name>
      <phone>55 5573 2911</phone>
      <phone_ext>21217</phone_ext>
      <email>julio.farjat@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Guering Edit Lid, M.D.</last_name>
      <phone>55 5573 2911</phone>
      <phone_ext>21217</phone_ext>
      <email>guering@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos A Aguila Bravo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana I Becerril Lechuga, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathia E Estrada López, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María E Soto López, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Gaspar, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 19, 2020</last_update_submitted>
  <last_update_submitted_qc>September 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cardiologia Ignacio Chavez</investigator_affiliation>
    <investigator_full_name>Julio Ivan Farjat Pasos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Radial Artery Occlusion</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Transradial access</keyword>
  <keyword>Unfractionated Heparin</keyword>
  <keyword>Coronary angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual patient data will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

